倪曼

摘要：目的? 觀察非布司他與別嘌醇治療慢性腎臟病合并高尿酸血癥的臨床療效和安全性。方法? 選取2018年8月～2019年8月在我院診治的106例慢性腎臟病合并高尿酸血癥患者為研究對象，將其隨機(jī)分為對照組和觀察組，各53例。對照組采用別嘌醇治療，觀察組采用非布司他治療，比較兩組臨床治療總有效率、治療前后血肌酐、血尿酸水平、平均血尿酸降低50%、血肌酐降低10%時(shí)間及臨床不良反應(yīng)發(fā)生情況。結(jié)果? 觀察組治療總有效率為94.33%，高于對照組的81.13%（P<0.05）;治療后兩組血肌酐、血尿酸水平均低于治療前，且觀察組低于對照組（P<0.05）;觀察組平均血尿酸降低50%、血肌酐降低10%時(shí)間均短于對照組（P<0.05）;兩組不良反應(yīng)發(fā)生率比較，差異無統(tǒng)計(jì)學(xué)意義（P>0.05）。結(jié)論? 非布司他治療慢性腎臟病合并高尿酸血癥療效優(yōu)于別嘌醇，有助于在短時(shí)間內(nèi)改善血尿酸和血肌酐水平，且臨床不良反應(yīng)少，應(yīng)用安全可靠。

關(guān)鍵詞：非布司他;別嘌醇;慢性腎臟病;高尿酸血癥

中圖分類號：R589.7;R692? ? ? ? ? ? ? ? ? ? ? ? ? ? 文獻(xiàn)標(biāo)識碼：A? ? ? ? ? ? ? ? ? ? ? ? ? ? ?DOI：10.3969/j.issn.1006-1959.2020.15.043

文章編號：1006-1959（2020）15-0140-02

Abstract：Objective? To observe the clinical efficacy and safety of febuxostat tablets and allopurinol in the treatment of chronic kidney disease with hyperuricemia.Methods? A total of 106 patients with chronic kidney disease and hyperuricemia who were diagnosed and treated in our hospital from August 2018 to August 2019 were selected as the research subjects， and they were randomly divided into a control group and an observation group， with 53 cases in each. The control group was treated with allopurinol， and the observation group was treated with febuxostat tablets.The total effective rate of clinical treatment， blood creatinine and blood uric acid levels before and after treatment， average blood uric acid reduction by 50%， blood creatinine reduction by 10% time and clinical the occurrence of adverse reactions.Results? The total effective rate of treatment in the observation group was 94.33%， which was higher than 81.13% in the control group（P<0.05）. After treatment， the blood creatinine and blood uric acid levels of the two groups were lower than before treatment， and the observation group was lower than In the control group（P<0.05）; in the observation group， the average blood uric acid decreased by 50% and the blood creatinine decreased by 10% were shorter than the control group （P<0.05）; adverse reactions between the two groups incidence rate was not statistically significant （P>0.05）.Conclusion? Febuxostat tablets is more effective than allopurinol in the treatment of chronic kidney disease with hyperuricemia. It is helpful to improve blood uric acid and blood creatinine levels in a short period of time， with few clinical adverse reactions and safe and reliable application.